Comparing survival in trial‐ versus routine‐care advanced urothelial cancer patients on immune checkpoint blockade
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.5798 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Lucy S Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Abramson Cancer Center.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
Although recent trials involving first‐line immune checkpoint inhibitors have expanded treatment options for patients with advanced urothelial carcinoma (aUC) who are ineligible for standard cisplatin‐based chemotherapy, there exists limited evidence for whether trial efficacy translates into real‐world effectiveness for patients seen in routine care. This retrospective cohort study compares differences in overall survival (OS) between KEYNOTE‐052 trial participants and routine‐care patients receiving first‐line pembrolizumab monotherapy.
Methods
A routine‐care patient cohort was constructed from the Flatiron Health database using trial eligibility criteria and was weighted to balance EHR and trial patient characteristics using matching‐adjusted indirect comparisons.
Results
The routine‐care cohort was older, more likely to be female, and more often cisplatin‐ineligible due to renal dysfunction. ECOG performance status was comparable between the cohorts. Median OS was 9 months (95% CI 7–16) in the weighted routine‐care cohort and 11.3 months (9.7–13.1) in the trial cohort. No significant differences between the Kaplan–Meier OS curves were detected ( p = 0.76). Survival probabilities were similar between the weighted routine‐care and trial cohorts at 12‐, 24‐, and 36‐ months (0.45 vs. 0.47, 0.31 vs. 0.31, 0.26 vs. 0.23, respectively). Notably, routine care patients had modestly lower survival at 3 months compared to trial participants (0.69 vs. 0.83, respectively).
Conclusion
Our results provide reassurance that cisplatin‐ineligible aUC patients receiving first‐line immunotherapy in routine care experience similar benefits to those observed in trial patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Biostatistics, Epidemiology, & Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Lucy S Wang
Förderung
- NCI NIH HHS
- Abramson Cancer Center
Zitieren
APA
Wang, L. S., Hubbard, R. A., & Mamtani, R. (2024). Comparing survival in trial‐ versus routine‐care advanced urothelial cancer patients on immune checkpoint blockade. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5798
Vancouver
Wang LS, Hubbard RA, Mamtani R. Comparing survival in trial‐ versus routine‐care advanced urothelial cancer patients on immune checkpoint blockade. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5798
BibTeX
@article{Wang2024,
author = {Wang, Lucy S and Hubbard, Rebecca A and Mamtani, Ronac},
title = {Comparing survival in trial‐ versus routine‐care advanced urothelial cancer patients on immune checkpoint blockade},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.5798}
}
EUVIMED